Form 4: Adverum Biotechnologies Director Granted Stock Options

Adverum Biotechnologies, Inc. Director Reed Vaughn Tuckson was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Summary

• Reed Vaughn Tuckson, a Director at Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The stock options have an exercise price of $2.32 per share.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent upon Mr. Tuckson's continued service with the Issuer on the vesting date.
• Accelerated vesting will occur upon a change of control.
• The options have an expiration date of June 16, 2035.
• Following this transaction, Mr. Tuckson beneficially owns 10,450 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a stock option grant is a standard compensation event, it aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance of Adverum Biotechnologies, Inc.
• It serves as a form of compensation and retention for a key member of the company's leadership.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a standard aspect of equity compensation.

Future Outlook

The stock options granted to Director Reed Vaughn Tuckson are set to vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, contingent on his continued service. These options will expire on June 16, 2035, and include a provision for accelerated vesting upon a change of control.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology industry for executive and board compensation. Such grants are designed to incentivize long-term performance and align leadership interests with shareholder value.

Related Party Transactions

• The grant of stock options to Reed Vaughn Tuckson, a Director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise of options, but also benefit from aligned director incentives.
• Employees: No direct impact mentioned, but standard compensation practices can influence overall company culture and talent retention strategies.
• Management: The director's compensation structure is enhanced, aligning their financial interests with the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service.
• Upon vesting, the director will have the right to exercise the options to purchase common stock at the specified exercise price.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology